Eli Lilly Targets Amylin Pathway to Unlock Next Generation Obesity Drug Combinations
Eli Lilly (LLY) reported early Phase 2 trial results for eloralintide, an obesity drug targeting the amylin pathway. Patients on the highest-dose combo lost 23.3% body weight vs. 14.8% on tirzepatide alone. Lilly plans standalone launch in 2029 and combo in 2030. Analyst David Risinger forecasts $23.2B annual sales by 2035. Q2 revenue grew 48%, with Zepbound and Mounjaro generating $14.9B. Lilly raised 2026 revenue guidance to $85B-$87B and EPS to $35.50-$36.50.
How this was made
The 30-second read
Why it matters
The Phase 2 data provides early validation but the timeline to market (2029‑2030) limits immediate trading opportunities.
Market read
Adds a new growth engine to Lilly's pipeline, may influence long‑term valuation and sector dynamics.
What to watch
Potential regulatory hurdles and competition from Novo's amylin programs may limit market share.
Background
Eli Lilly is expanding its obesity portfolio beyond GLP‑1 drugs, targeting the amylin pathway with eloralintide.
Ticker impact
Eli Lilly disclosed early Phase 2 results for its experimental obesity drug eloralintide, showing 23.3% weight loss versus 14.8% for tirzepatide.
limited near‑term pressure, potential upside as investors price in future growth
The trial data is novel and favorable, yet the product is years from launch, so immediate market reaction is muted.
Market effects
Strengthens the obesity‑treatment segment and may pressure peers developing GLP‑1 alternatives.
U.S. biotech sector sees modest uplift; European peers may feel competitive pressure.
Adds to global obesity‑drug pipeline narrative, relevant for investors worldwide.
Counterpoint
The small trial size and higher discontinuation rates could signal safety concerns that outweigh efficacy benefits.
Key entities
- companyEli Lilly
U.S. pharmaceutical company developing obesity treatments.
- companyNovo Nordisk
Competitor also pursuing amylin‑based obesity drugs.
